Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cardiol Therapeutics Inc CRDL


Primary Symbol: T.CRDL

Cardiol Therapeutics Inc. is a clinical-stage life sciences company. The Company is focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. It is also developing CRD-38, a novel subcutaneously administered drug intended for use in heart failure. It has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart.


TSX:CRDL - Post by User

Post by Youhillmanon Mar 16, 2021 12:01am
178 Views
Post# 32805380

Today’s Renmark Virtual Presentation

Today’s Renmark Virtual Presentation

Took in the presentation by Elsley today, the most noteworthy point to me was the fact that he was asked a question concerning an ETF that had bought a number of CRDL shares last week.

Elsley was aware of it, said it was several thousand shares, but he didn't know the exact number nor the ETF and suggested contacting their IR Department to get the details.

I've looked into it, the ETF is called 'The Cannabis ETF', the ticker is THCK on the NYSE and the number of shares held is over one Million.

Obviously this company / ETF loves the CRDL story!

Looking forward to seeing the NASDAQ listing next month, that should take the share price closer to $8-10.

<< Previous
Bullboard Posts
Next >>